Apr 01, 2026
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home SettingVIEW RELEASE
Mar 27, 2026
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient SettingVIEW RELEASE
Mar 11, 2026
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct OfferingVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Apr 01, 2026 02:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.21
CHANGE
-0.14 (-10.07%)
